O'Shaughnessy Asset Management’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

O'Shaughnessy Asset Management’s Portfolio ITCI Stock Details ITCI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-5,768	Closed	-$761K	–	2525
2025 Q1	$761K	Buy	+5,768	New	+$719K	0.01%	1118
2024 Q3	–	Sell	-3,674	Closed	-$252K	–	2206
2024 Q2	$252K	Sell	3,674 -255	-6%	-$17.7K	﹤0.01%	1447
2024 Q1	$272K	Buy	3,929 +75	+2%	+$5.16K	﹤0.01%	1364
2023 Q4	$276K	Buy	+3,854	New	+$222K	﹤0.01%	1249
2023 Q1	–	Sell	-3,970	Closed	-$210K	–	1546
2022 Q4	$210K	Buy	+3,970	New	+$199K	﹤0.01%	1101
2022 Q3	–	Sell	-4,084	Closed	-$233K	–	1426
2022 Q2	$233K	Buy	4,084 +6	+0.1%	+$340	﹤0.01%	969
2022 Q1	$250K	Buy	+4,078	New	+$212K	﹤0.01%	974

Other funds holding ITCI

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

KIM

Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

O'Shaughnessy Asset Management's ITCI Position: Q2 2025 in Review

O'Shaughnessy Asset Management sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 5,768 shares — an estimated $761K sold.

O'Shaughnessy Asset Management first reported a position in ITCI in Q1 2022 and held it in 7 quarters. The position peaked at $761K in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

O'Shaughnessy Asset Management reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
O'Shaughnessy Asset Management sold 5,768 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $761K.
O'Shaughnessy Asset Management first reported a position in Intra-Cellular Therapies Inc. in Q1 2022 and held it in 7 quarters.
O'Shaughnessy Asset Management's Intra-Cellular Therapies Inc. position peaked at $761K in Q1 2025.
4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on O'Shaughnessy Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.